114 related articles for article (PubMed ID: 8674057)
1. Phase I clinical trial with a human major histocompatibility complex nonrestricted cytotoxic T-cell line (TALL-104) in dogs with advanced tumors.
Cesano A; Visonneau S; Jeglum KA; Owen J; Wilkinson K; Carner K; Reese L; Santoli D
Cancer Res; 1996 Jul; 56(13):3021-9. PubMed ID: 8674057
[TBL] [Abstract][Full Text] [Related]
2. Successful treatment of canine malignant histiocytosis with the human major histocompatibility complex nonrestricted cytotoxic T-cell line TALL-104.
Visonneau S; Cesano A; Tran T; Jeglum KA; Santoli D
Clin Cancer Res; 1997 Oct; 3(10):1789-97. PubMed ID: 9815565
[TBL] [Abstract][Full Text] [Related]
3. Antitumor efficacy of a human major histocompatibility complex nonrestricted cytotoxic T-cell line (TALL-104) in immunocompetent mice bearing syngeneic leukemia.
Cesano A; Visonneau S; Pasquini S; Rovera G; Santoli D
Cancer Res; 1996 Oct; 56(19):4444-52. PubMed ID: 8813139
[TBL] [Abstract][Full Text] [Related]
4. Phase I trial of TALL-104 cells in patients with refractory metastatic breast cancer.
Visonneau S; Cesano A; Porter DL; Luger SL; Schuchter L; Kamoun M; Torosian MH; Duffy K; Sickles C; Stadtmauer EA; Santoli D
Clin Cancer Res; 2000 May; 6(5):1744-54. PubMed ID: 10815893
[TBL] [Abstract][Full Text] [Related]
5. Treatment of experimental glioblastoma with a human major histocompatibility complex nonrestricted cytotoxic T cell line.
Cesano A; Visonneau S; Santoli D
Cancer Res; 1995 Jan; 55(1):96-101. PubMed ID: 7805048
[TBL] [Abstract][Full Text] [Related]
6. TALL-104 cell therapy of human solid tumors implanted in immunodeficient (SCID) mice.
Cesano A; Visonneau S; Santoli D
Anticancer Res; 1998; 18(4A):2289-95. PubMed ID: 9703868
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant treatment of canine osteosarcoma with the human cytotoxic T-cell line TALL-104.
Visonneau S; Cesano A; Jeglum KA; Santoli D
Clin Cancer Res; 1999 Jul; 5(7):1868-75. PubMed ID: 10430094
[TBL] [Abstract][Full Text] [Related]
8. Toxicological and immunological evaluation of the MHC-non-restricted cytotoxic T cell line TALL-104.
Cesano A; Visonneau S; Wolfe JH; Jeglum KA; Fernandez J; Gillio A; O'Reilly RJ; Santoli D
Cancer Immunol Immunother; 1997 May; 44(3):125-36. PubMed ID: 9191872
[TBL] [Abstract][Full Text] [Related]
9. Increased non-major histocompatibility complex-restricted lytic activity in melanoma patients vaccinated with cytokine gene-transfected autologous tumor cells.
Möller P; Möller H; Sun Y; Dorbic T; Henz BM; Wittig B; Schadendorf D
Cancer Gene Ther; 2000 Jul; 7(7):976-84. PubMed ID: 10917199
[TBL] [Abstract][Full Text] [Related]
10. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
[TBL] [Abstract][Full Text] [Related]
11. The human leukemic T-cell line, TALL-104, is cytotoxic to human malignant brain tumors and traffics through brain tissue: implications for local adoptive immunotherapy.
Kruse CA; Visonneau S; Kleinschmidt-DeMasters BK; Gup CJ; Gomez GG; Paul DB; Santoli D
Cancer Res; 2000 Oct; 60(20):5731-9. PubMed ID: 11059767
[TBL] [Abstract][Full Text] [Related]
12. NTP Toxicology and Carcinogenesis Studies of o-Benzyl-p-Chlorophenol (CAS No. 120-32-1) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1994 Jan; 424():1-304. PubMed ID: 12616287
[TBL] [Abstract][Full Text] [Related]
13. [The repetitive immune cell transfer therapy combining non-myelosuppressive chemotherapy for patients with advanced and refractory cancer].
Toh U; Fujii T; Tayama K; Yanaga H; Yokoyama G; Yamaguchi M; Horiuchi H; Sasatomi T; Takamori S; Shirouzu K; Seki N; Yamana H
Gan To Kagaku Ryoho; 2004 Oct; 31(11):1649-51. PubMed ID: 15553672
[TBL] [Abstract][Full Text] [Related]
14. Cell therapy of a highly invasive human breast carcinoma implanted in immunodeficient (SCID) mice.
Visonneau S; Cesano A; Torosian MH; Santoli D
Clin Cancer Res; 1997 Sep; 3(9):1491-500. PubMed ID: 9815835
[TBL] [Abstract][Full Text] [Related]
15. Effects of development of host immunity on the biodistribution of xenogeneic MHC non-restricted cytotoxic T cells: implications for adoptive cell therapy of cancer.
Cesano A; Wortman JA; Pourdehnad M; Visonneau S; Mozley D; Bhatnagar A; Alavi A; Santoli D
Int J Oncol; 1999 Feb; 14(2):233-44. PubMed ID: 9917497
[TBL] [Abstract][Full Text] [Related]
16. A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma.
Leemhuis T; Wells S; Scheffold C; Edinger M; Negrin RS
Biol Blood Marrow Transplant; 2005 Mar; 11(3):181-7. PubMed ID: 15744236
[TBL] [Abstract][Full Text] [Related]
17. Use of a lethally irradiated major histocompatibility complex nonrestricted cytotoxic T-cell line for effective purging of marrows containing lysis-sensitive or -resistant leukemic targets.
Cesano A; Pierson G; Visonneau S; Migliaccio AR; Santoli D
Blood; 1996 Jan; 87(1):393-403. PubMed ID: 8547668
[TBL] [Abstract][Full Text] [Related]
18. Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies.
London CA; Hannah AL; Zadovoskaya R; Chien MB; Kollias-Baker C; Rosenberg M; Downing S; Post G; Boucher J; Shenoy N; Mendel DB; McMahon G; Cherrington JM
Clin Cancer Res; 2003 Jul; 9(7):2755-68. PubMed ID: 12855656
[TBL] [Abstract][Full Text] [Related]
19. NTP technical report on the toxicity studies of Dibutyl Phthalate (CAS No. 84-74-2) Administered in Feed to F344/N Rats and B6C3F1 Mice.
Marsman D
Toxic Rep Ser; 1995 Apr; 30():1-G5. PubMed ID: 12209194
[TBL] [Abstract][Full Text] [Related]
20. Synergistic effects of adriamycin and TALL-104 cell therapy against a human gastric carcinoma in vivo.
Cesano A; Visonneau S; Rovera G; Santoli D
Anticancer Res; 1997; 17(3C):1887-92. PubMed ID: 9216640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]